Search results
Study ties prevalence of drug-resistant organisms to socioeconomic conditions
Center for Infectious Disease Research and Policy· 2 days agoA study in Texas found a higher prevalence of AMR organisms in areas with high levels of economic...
Moderna, Merck shares rise as combined melanoma therapy shows improved survival rate By...
Investing.com· 6 days agoModerna (NASDAQ:MRNA) and Merck (MRK) have released new, more encouraging three-year data on their...
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say
WSAU Wausau· 5 days ago(Reuters) - COVID-19 vaccine makers said data from animals studies showed their 2024-25 shots...
An mRNA Melanoma Vaccine Shows Promise
Time Magazine· 7 days agoIn the study, Moderna and Merck combined their cancer treatments—Moderna’s experimental cancer vaccine and Merck’s approved checkpoint inhibitor...
5 million doses of vaccine against H5N1 avian flu being prepared
UPI· 6 days agoThe new vaccine doses combine an antigen that targets the H5 portion of the H5N1 virus with an...
Sierra Leone gets first doses of a malaria vaccine – but with major challenges ahead
Daily Telegraph· 5 days agoDespite this, constant efforts from the government, its NGO partners, and leaders within local...
Michael Mosley: How the presenter transformed people's lives
BBC via Yahoo News· 6 hours ago“I discovered that almost all the great medical discoveries were made by self-experimenters, whether...
NHS England launches pioneering trials for world-first cancer vaccine
BioPharma-Reporter· 7 days agoTo date, thirty hospitals have joined NHS England's Cancer Vaccine Launch Pad, which aims to...
What To Know About Personalized mRNA Cancer Vaccines After Promising Trials From Moderna And Merck
Forbes· 6 days agoCancer vaccines are finally showing promise as Moderna and Merck touted promising data on an...
FDA Panel to Consider Which COVID Strain to Target in an Updated Vaccine
MedPage Today· 7 days agoThe current predominant strain of COVID-19 should be a key consideration during the upcoming meeting...